Chemical Peritonitis following the Intraperitoneal Administration of Vancomycin
| Autor: | Theresa Greene Reed, Ermona B. McGoodwin, Joel P. Freiman, David J. Graham |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
medicine.medical_specialty
Abdominal pain medicine.drug_class business.industry medicine.medical_treatment Vancomycin Hydrochloride Antibiotics Peritonitis General Medicine medicine.disease Gastroenterology Surgery Peritoneal dialysis Nephrology Chemical Peritonitis Internal medicine medicine Vancomycin medicine.symptom Adverse effect business medicine.drug |
| Zdroj: | Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. 12:57-60 |
| ISSN: | 1718-4304 0896-8608 |
| DOI: | 10.1177/089686089201200113 |
| Popis: | The Food and Drug Administration has received 51 reports of cases in the United States in which chemical peritonitis was associated with the intraperitoneal administration of sterile vancomycin hydrochloride, USP intravenous. The clinical presentation of the cases ranged from mild (cloudy dialysate alone) to more severe (severe abdominal pain and fever). The temporal circumstances suggest that intraperitoneal vancomycin may be associated with chemical peritonitis. A positive rechallenge was reported in 9 cases. The underlying mechanism responsible for this adverse reaction has not yet been identified. Several adverse reaction reports have been submitted to the Food and Drug Administration (FDA) concerning the development of chemical peritonitis in continuous ambulatory peritoneal dialysis (CAPD) patients following the intraperitoneal administration of sterile vancomycin hydrochloride, USP intravenous. The reactions reported ranged from mild (cloudy dialysate alone) to more severe (severe abdominal pain and fever). Although the majority of reactions were self-limited, some resulted in hospitalization and/or a prolongation of antibiotic therapy. Based upon these reaction reports, the FDA issued a Safety Alert Letter in May 1990 to all known dialysis centers in the United States (1). The purpose of this article is to provide additional clinical and laboratory data on the cases cited in the Safety Alert Letter. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|